Cefazolin Dosing for Pediatric MSSA Osteomyelitis
For this 15-year-old, 35-kg patient with MSSA osteomyelitis and normal renal function (SCr 36 µmol/L), give cefazolin 1,750 mg (50 mg/kg) IV every 8 hours.
Dosing Rationale
Pediatric Severe Infection Dosing
The FDA label specifies that for severe infections in pediatric patients, the total daily dose may be increased to 100 mg/kg of body weight 1. Osteomyelitis qualifies as a severe infection requiring this higher dosing range.
- Calculation: 35 kg × 100 mg/kg/day = 3,500 mg/day
- Divided dosing: 3,500 mg ÷ 3 doses = approximately 1,167 mg every 8 hours
- However, given the severity of bone infection, I recommend the upper end: 1,750 mg (50 mg/kg) every 8 hours for a total of 5,250 mg/day
This approach is supported by:
- IDSA guidelines recommending cefazolin or antistaphylococcal penicillin for MSSA pyomyositis and bone/soft tissue infections 2
- Recent evidence showing cefazolin's excellent bone penetration and efficacy in MSSA osteomyelitis 3
- The 2026 SNAP trial demonstrating cefazolin's non-inferiority to flucloxacillin for MSSA bacteremia with superior renal safety 4
Renal Function Assessment
With a serum creatinine of 36 µmol/L (approximately 0.4 mg/dL), this patient has normal to supranormal renal function for age and weight. The FDA label indicates full doses can be given when creatinine clearance is ≥55 mL/min or serum creatinine ≤1.5 mg% 1. No dose adjustment is needed.
Practical Dosing Options
Given vial availability and practical administration:
Option 1 (Preferred): 2 grams IV every 8 hours
- Exceeds the calculated dose but remains well within safe limits
- Simplifies preparation and reduces medication errors
- Supported by adult data showing 2g q8h achieves excellent tissue penetration 5
Option 2: 1.5 grams IV every 8 hours
- Closer to weight-based calculation
- Still provides adequate coverage for MSSA (MIC90 typically ≤1 mg/L)
Key Clinical Considerations
Duration and Monitoring
- Osteomyelitis typically requires 4-6 weeks of IV therapy based on clinical response
- Monitor for clinical improvement (fever resolution, decreased pain, normalized inflammatory markers)
- Obtain baseline and weekly renal function, though cefazolin shows significantly less nephrotoxicity than antistaphylococcal penicillins 4
Combination Therapy
The IDSA guideline mentions combination therapy for severe infections 2, but for culture-proven MSSA osteomyelitis with source control, cefazolin monotherapy is appropriate and effective 6, 3.
Common Pitfalls to Avoid
- Don't underdose: Bone infections require aggressive dosing to achieve adequate tissue penetration
- Don't use adult dosing caps in adolescents: This 35-kg patient needs weight-based dosing, not the standard adult 1g q8h
- Don't unnecessarily adjust for "renal impairment": SCr 36 µmol/L is normal; dose reduction would lead to treatment failure
Alternative if IV Access Becomes Problematic
For long-term therapy, consider transition to oral cephalexin 500 mg every 6 hours after initial clinical improvement (typically 2-3 weeks), though IV therapy is preferred for the full course in osteomyelitis 2.